When Will Verona Pharma Plc (NASDAQ:VRNA) Breakeven?
When Will Verona Pharma Plc (NASDAQ:VRNA) Breakeven?
We feel now is a pretty good time to analyse Verona Pharma plc's (NASDAQ:VRNA) business as it appears the company may be on the cusp of a considerable accomplishment. Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The US$1.2b market-cap company announced a latest loss of US$54m on 31 December 2023 for its most recent financial year result. Many investors are wondering about the rate at which Verona Pharma will turn a profit, with the big question being "when will the company breakeven?" Below we will provide a high-level summary of the industry analysts' expectations for the company.
我們認爲,現在是分析維羅納製藥公司(納斯達克股票代碼:VRNA)業務的好時機,因爲看來該公司可能正處於取得重大成就的風口浪尖。Verona Pharma plc是一家臨床階段的生物製藥公司,專注於治療醫療需求未得到滿足的呼吸系統疾病的療法的開發和商業化。這家市值爲12億美元的公司於2023年12月31日宣佈其最新財年業績虧損5400萬美元。許多投資者想知道維羅納製藥的盈利速度,最大的問題是 “公司何時會實現盈虧平衡?”下面,我們將概述行業分析師對公司的期望。
According to the 7 industry analysts covering Verona Pharma, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$161m in 2026. So, the company is predicted to breakeven approximately 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 59% year-on-year, on average, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
根據報道維羅納製藥的7位行業分析師的說法,人們的共識是盈虧平衡已接近尾聲。他們預計,該公司將在2025年蒙受最終虧損,然後在2026年產生1.61億美元的正利潤。因此,預計從今天起大約兩年後,該公司將實現盈虧平衡。爲了在2026年之前達到盈虧平衡點,公司每年必須以多快的速度增長?從分析師的估計來看,事實證明,他們預計公司平均同比增長59%,這相當樂觀!如果事實證明這個利率過於激進,該公司的盈利時間可能比分析師預測的要晚得多。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240426/0-7d8fed7916f077da5e7f9db711280a23-0-624a1f73391156e747a154f6174292d7.png/big)
We're not going to go through company-specific developments for Verona Pharma given that this is a high-level summary, however, take into account that typically a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
鑑於這是一份高層次的摘要,我們不打算詳細介紹維羅納製藥公司的具體發展情況,但是,要考慮到製藥公司的現金流通常不穩定,這取決於業務所處的藥物和產品開發階段。這意味着,隨着公司開始從先前的投資中受益,即將到來的大幅增長率並不異常。
Before we wrap up, there's one aspect worth mentioning. The company has managed its capital prudently, with debt making up 19% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.
在我們總結之前,有一個方面值得一提。該公司謹慎地管理了資本,債務佔股權的19%。這意味着其運營資金主要來自股權資本,其低債務債務降低了投資這家虧損公司的風險。
Next Steps:
後續步驟:
This article is not intended to be a comprehensive analysis on Verona Pharma, so if you are interested in understanding the company at a deeper level, take a look at Verona Pharma's company page on Simply Wall St. We've also put together a list of pertinent aspects you should look at:
本文無意對維羅納製藥進行全面分析,因此,如果你有興趣更深入地了解該公司,請查看維羅納製藥公司在Simply Wall St上的公司頁面。我們還整理了一份你應該考慮的相關方面清單:
- Historical Track Record: What has Verona Pharma's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Verona Pharma's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 歷史記錄:維羅納製藥公司過去的表現如何?詳細了解過去的往績分析,並查看我們分析的免費可視化表示,以提高清晰度。
- 管理團隊:一支經驗豐富的管理團隊掌舵增強了我們對業務的信心——看看誰是維羅納製藥董事會成員和首席執行官的背景。
- 其他表現優異的股票:還有其他股票可以提供更好的前景並有良好的往績記錄嗎?在這裏瀏覽我們免費列出的這些優質股票。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。